Related Experiment Video

Updated: Oct 13, 2026

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)

Published on: December 19, 2019

Antitumor-promoting effects of cyclic diarylheptanoids on Epstein-Barr virus activation and two-stage mouse skin

J Ishida1, M Kozuka, H Wang

  • 1Natural Products Laboratory, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7360, USA.

Cancer Letters
|September 21, 2000
PubMed

Insights

Eleven cyclic diarylheptanoids were evaluated for antitumor promotion. 13-Oxomyricanol and myricanone demonstrated significant inhibitory effects against Epstein-Barr virus activation and skin tumor development, suggesting their potential as chemopreventive agents.

Area of Science:

  • Natural Products Chemistry
  • Pharmacology
  • Oncology

Background:

  • Epstein-Barr virus (EBV) activation is a target for antitumor promotion research.
  • Natural compounds are explored for their chemopreventive potential.
  • Cyclic diarylheptanoids represent a class of natural products with potential biological activities.

Purpose of the Study:

  • To screen cyclic diarylheptanoids for antitumor promoting activity.
  • To evaluate the inhibitory effects of these compounds on Epstein-Barr virus early antigen activation.
  • To assess their efficacy in a mouse skin carcinogenesis model.

Main Methods:

  • Eleven cyclic diarylheptanoids were tested for their ability to inhibit 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced Epstein-Barr virus early antigen activation in Raji cells.
  • The most active compounds were further evaluated in a two-stage mouse skin carcinogenesis test.

Main Results:

  • 13-Oxomyricanol and myricanone exhibited the highest inhibitory activity against EBV early antigen activation.
  • These two compounds also demonstrated significant inhibitory effects on mouse skin tumor promotion in vivo.
  • The results indicate a dose-dependent inhibitory effect for the active compounds.

Conclusions:

  • Certain cyclic diarylheptanoids, specifically 13-Oxomyricanol and myricanone, possess significant antitumor promoting properties.
  • These compounds show promise as potential chemopreventive agents against cancer.
  • Further investigation into the mechanisms of action of these diarylheptanoids is warranted.

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Isolation of Mouse Epidermal Keratinocytes and Their In Vitro Clonogenic Culture06:16

Isolation of Mouse Epidermal Keratinocytes and Their In Vitro Clonogenic Culture

Published on: August 10, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...